Clinical Trial Update: Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with or without PRI-724 for newly diagnosed metastatic colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PRI-724 (PRI-724)

Snippet

Sponsor: University of Southern California | Conditions: Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer | Phase 2 | Status: WITHDRAWN